These Small-Cap Stocks Pay Juicier Dividends Than Many Big Names
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2024
0mins
Should l Buy JNJ?
Source: MarketWatch
- Large-cap Dividend Payers: Johnson & Johnson and PepsiCo are popular among income investors.
- Diversifying Dividend Investments: There are other dividend opportunities beyond large-cap stocks.
- Small-Cap Dividends: While less common, some small-cap stocks offer attractive valuations, good yields, and a history of increasing dividends.
- Content Limitation: The full content requires subscription or signing in to access.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 243.710
Low
190.00
Averages
218.50
High
240.00
Current: 243.710
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson's Tecnis PureSee intraocular lens has received FDA approval, marking it as the first extended depth of focus IOL, providing a new option for cataract surgery that is expected to enhance surgical outcomes and patient satisfaction.
- Visual Quality Improvement: The lens maintains contrast sensitivity, ensuring that patients can better differentiate objects from backgrounds post-surgery, thereby reducing dependence on glasses and improving overall quality of life for users.
- Positive User Feedback: JNJ reports that 97% of users have not experienced halos, glare, or other visual disturbances after implantation, indicating strong clinical performance that may drive increased market demand for the product.
- Product Line Expansion: Tecnis PureSee will be the latest addition to J&J's Tecnis lens portfolio, further enriching its product offerings and strengthening the company's competitive position in the ophthalmic market, which is expected to positively impact future sales.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson announced that its TECNIS PureSee IOL has received FDA approval as a new extended depth of focus intraocular lens for cataract surgery, marking an important new option for surgeons.
- Enhanced Visual Clarity: The TECNIS PureSee IOL allows 97% of patients to report no very bothersome visual disturbances, significantly improving visual quality and enhancing daily activities such as reading, driving, and recognizing faces.
- Dual Functionality: This lens addresses both cataract-related vision loss and presbyopia in a single procedure, showcasing its multifunctionality in ophthalmic surgery and further solidifying Johnson & Johnson's market position in the eye care sector.
- Global Recognition: The TECNIS PureSee IOL is approved worldwide, with nearly half a million eyes experiencing clearer vision after cataract surgery, demonstrating the product's broad acceptance and successful application in the global market.
See More
Johnson & Johnson Launches TECNIS PureSee IOL for Cataract Surgery
- FDA Approval: Johnson & Johnson's TECNIS PureSee IOL has received FDA approval, becoming the first extended depth of focus IOL with no warning on loss of contrast sensitivity, which is expected to significantly enhance patient visual quality and satisfaction.
- Positive Patient Feedback: With 97% of patients reporting no very bothersome visual disturbances and a similar percentage willing to recommend the product to friends or family, the TECNIS PureSee IOL demonstrates high potential acceptance and trust in the market.
- Significant Market Demand: Approximately 94 million people aged 50 and over suffer from moderate to severe distance vision impairment, and the introduction of TECNIS PureSee IOL will provide an effective visual solution for these patients, addressing the growing market demand.
- Technological Innovation Advantage: The TECNIS PureSee IOL combines advanced optical technology with proprietary materials to effectively mitigate the effects of presbyopia, offering excellent distance, intermediate, and near vision, thereby further solidifying Johnson & Johnson's leadership in the surgical vision sector.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
FDA Approves Expanded Use of Wellcovorin for Cerebral Folate Deficiency
- Drug Indication Expansion: The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in both adult and pediatric patients with confirmed FOLR1 gene variants, marking a significant advancement in the treatment of rare neurological diseases.
- First Treatment Option: Wellcovorin becomes the first drug specifically indicated for cerebral folate deficiency, addressing common autism-like symptoms and severe developmental delays in patients, thereby offering new hope for improving their quality of life.
- Scientific Basis for Approval: The FDA's approval was based on a systematic review of the literature, including patient-level information and mechanistic data, demonstrating the drug's efficacy and safety in clinical applications, which enhances confidence in its use.
- Market Impact: Although GSK no longer manufactures Wellcovorin, the expanded approval allows generic versions to carry the new indication, which is expected to drive demand in the market and enhance treatment options for patients with cerebral folate deficiency.
See More
Johnson & Johnson's AKEEGA Approved by European Commission
- Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
- Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
- Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
- Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson's Tecnis PureSee intraocular lens has received FDA approval, marking it as the first extended depth of focus IOL, providing a new option for cataract surgery that is expected to enhance surgical outcomes and patient satisfaction.
- Visual Quality Improvement: The lens maintains contrast sensitivity, ensuring that patients can better differentiate objects from backgrounds post-surgery, thereby reducing dependence on glasses and improving overall quality of life for users.
- Positive User Feedback: JNJ reports that 97% of users have not experienced halos, glare, or other visual disturbances after implantation, indicating strong clinical performance that may drive increased market demand for the product.
- Product Line Expansion: Tecnis PureSee will be the latest addition to J&J's Tecnis lens portfolio, further enriching its product offerings and strengthening the company's competitive position in the ophthalmic market, which is expected to positively impact future sales.
See More
Johnson & Johnson Receives FDA Approval for New Intraocular Lens
- FDA Approval: Johnson & Johnson announced that its TECNIS PureSee IOL has received FDA approval as a new extended depth of focus intraocular lens for cataract surgery, marking an important new option for surgeons.
- Enhanced Visual Clarity: The TECNIS PureSee IOL allows 97% of patients to report no very bothersome visual disturbances, significantly improving visual quality and enhancing daily activities such as reading, driving, and recognizing faces.
- Dual Functionality: This lens addresses both cataract-related vision loss and presbyopia in a single procedure, showcasing its multifunctionality in ophthalmic surgery and further solidifying Johnson & Johnson's market position in the eye care sector.
- Global Recognition: The TECNIS PureSee IOL is approved worldwide, with nearly half a million eyes experiencing clearer vision after cataract surgery, demonstrating the product's broad acceptance and successful application in the global market.
See More
Johnson & Johnson Launches TECNIS PureSee IOL for Cataract Surgery
- FDA Approval: Johnson & Johnson's TECNIS PureSee IOL has received FDA approval, becoming the first extended depth of focus IOL with no warning on loss of contrast sensitivity, which is expected to significantly enhance patient visual quality and satisfaction.
- Positive Patient Feedback: With 97% of patients reporting no very bothersome visual disturbances and a similar percentage willing to recommend the product to friends or family, the TECNIS PureSee IOL demonstrates high potential acceptance and trust in the market.
- Significant Market Demand: Approximately 94 million people aged 50 and over suffer from moderate to severe distance vision impairment, and the introduction of TECNIS PureSee IOL will provide an effective visual solution for these patients, addressing the growing market demand.
- Technological Innovation Advantage: The TECNIS PureSee IOL combines advanced optical technology with proprietary materials to effectively mitigate the effects of presbyopia, offering excellent distance, intermediate, and near vision, thereby further solidifying Johnson & Johnson's leadership in the surgical vision sector.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
FDA Approves Expanded Use of Wellcovorin for Cerebral Folate Deficiency
- Drug Indication Expansion: The FDA has approved Wellcovorin (leucovorin calcium) for treating cerebral folate deficiency in both adult and pediatric patients with confirmed FOLR1 gene variants, marking a significant advancement in the treatment of rare neurological diseases.
- First Treatment Option: Wellcovorin becomes the first drug specifically indicated for cerebral folate deficiency, addressing common autism-like symptoms and severe developmental delays in patients, thereby offering new hope for improving their quality of life.
- Scientific Basis for Approval: The FDA's approval was based on a systematic review of the literature, including patient-level information and mechanistic data, demonstrating the drug's efficacy and safety in clinical applications, which enhances confidence in its use.
- Market Impact: Although GSK no longer manufactures Wellcovorin, the expanded approval allows generic versions to carry the new indication, which is expected to drive demand in the market and enhance treatment options for patients with cerebral folate deficiency.
See More
Johnson & Johnson's AKEEGA Approved by European Commission
- Drug Approval: Johnson & Johnson announced that its dual-action drug AKEEGA has been approved by the European Commission for treating adult patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer, marking a significant advancement in cancer treatment.
- Clinical Trial Support: The approval is supported by data from the Phase 3 AMPLITUDE trial, which demonstrated significant benefits in BRCA-mutated patients, further solidifying its application potential in high-risk patient groups.
- Market Outlook: According to GlobalData's Pharma Intelligence Centre, AKEEGA is projected to generate $178 million in revenue by 2031, indicating strong growth potential for Johnson & Johnson in the prostate cancer treatment market.
- Stock Performance: Johnson & Johnson's stock has traded between $141.50 and $251.71 over the past year, with the latest closing price at $240.40, reflecting positive market sentiment following the drug approval.
See More
